Expression of proteins correlated with the unique cisplatin sensitivity of testicular cancer

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 369-375

  De Graaf, T W ^a   De Jong, S ^a   De Vries, E G E ^a   Mulder, N H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cisplatin; Drug resistance; Human; Protein; Testicular cancer; Two dimensional gel electrophoresis

Indexed keywords

CELL PROTEIN; CISPLATIN; LACTATE DEHYDROGENASE;

ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; GERM CELL; HUMAN; HUMAN CELL; LUNG CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TESTIS CANCER;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CISPLATIN; DRUG RESISTANCE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; MALE; NEOPLASM PROTEINS; TESTICULAR NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0031043744     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. McLaughlin K, Coren G, Masters J, et al: Binding activities of cisplatin-damagerecognition proteins in human tumour cell lines. Int J Cancer 55: 662-666, 1993.
2. Yang L-Y, Trujillo JM, Siciliano MJ, et al: Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cisdiamminedichloroplatinum (II). Int J Cancer 53: 478-485, 1993.
3. Mellish KJ, Kelland LR, Harrap KR: In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancc. 58: 240-250, 1993.
4. Chao CC-K: Potential negative regulation of damage-recognition proteins in cisplatinresistant HeLa cells in response to DNA damage. Mutat Res 264: 59-66, 1991.
5. Ogawa J-I, Iwazaki M, Inoue H, et al: Immunohistochemical study of glutathionerelated enzymes and proliferative antigens in lung cancer. Cancer 71: 2204-2209, 1993.
6. Hirata J, Kikuchi Y, Kita T, et al: Modulation of sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum (II) by 12-O- tetradecanoylphorbol-13-acetate and D,L-buthionine-S,R-sulphoximine. Int J Cancer 55: 521-527, 1993.
7. Terheggen PMAB, Emondt JY, Floot BGJ, et al: Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res 50: 3556-3561, 1990.
8. Sark MWJ, Timmer-Bosscha H, Meijer C, et al: Cellular basis for differential sensitivity to cisplatin in human germ cell cancer and colon cancer cell lines. Br J Cancer 71: 684-690, 1995.
9. Timmer-Bosscha H, Timmer A, Meijer C, et al: cis-Diamminedichloroplatinum(II) resistance in vitro and in vivo in human embryonal carcinoma cells. Cancer Res 53: 5707-5713, 1993.
10. Meijer C, Mulder NH, Hospers GAP et al: The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br J Cancer 62: 72-77, 1990.
11. Hospers GAP, Mulder NH, De Jong B, et al: Characterization of a human small cell lung carcinoma cell line with acquired cisplatin resistance in vitro. Cancer Res 48: 6803-6807, 1988.
12. Hospers GAP, De Vries EGE, Mulder NH: The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (hSCLC) cell line. Br J Cancer 67: 79-82, 1990.
13. Hospers GAP, Meijer C, De Leij L, et al: A study on human small cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance. Int J Cancer 46: 138-144, 1990.
14. Bronson DL, Andrews PW, Solter D, et al: Cell line derived from a metastasis of a human testicular germ cell tumor. Cancer Res 40: 2500-2506, 1980.
15. Andrews PW, Damjanov I, Simon D, et al: Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line tera-2. Differentiation in vivo and in vitro. J Lab Invest 50: 147-162, 1984.
16. Meijer C, Mulder NH, Timmer-Bosscha H, et al: Relationship of cellular glutathione to the cytotoxicity and the resistance of seven platinum compounds. Cancer Res 52: 6885-6889, 1992.
17. Leibovitz A, Stinson JC, McCombs (III) WB, et al: Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562-4569, 1976.
18. Fogh J, Wright WC, Loveless JD, et al: Absence of Hela contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58: 209-214, 1977.
19. O'Farrell PH: High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250: 4007-4021, 1975.
20. Wright WD and Roti JL: Resolution of DNA topoisomerase II by two-dimensional polyacrylamide gel electrophoresis and western blotting. Anal Biochcm 204: 124-130, 1992.
21. Celis JE, Leffers H, Holm Rasmussen H, et al: The master twodimensional gel database of human AMA cell proteins: Towards linking protein and genome sequence and mapping information: Update 1991. Electrophoresis 12: 765-801, 1991.
22. Celis JE, Holm Rasmussen H, Olsen E, et al: The human keratinocyte two-dimensional gel protein database: Update 1993. Electrophoresis 14: 1091-1198, 1993.
23. Blanco A, Zinkman WH: Lactate dehydrogenises in human testes. Science 139: 601-602, 1963.
24. Sarnow P, Shin Ho Y, Williams J, et al: Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28: 387-394, 1982.
25. Katabami M, Fujita H, Honke K, et al: Marked reduction of type I keratin (K14) in cisplatin-resistant human lung squamous-carcinoma cell lines. Biochem Pharmacol 45: 1703-1710, 1993.
26. Prives C and Manfredi, JJ: The p53 tumor suppressor protein: meeting review. Genes Develop 7: 529-534, 1993.
27. Poller DN, Hutchings CE, Galea M, et al: p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer 66: 583-588, 1992.
28. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253: 49-53, 1991.
29. Fritsche M, Haessler C, Brandner G: Induction of nuclear accumulation of the tumorsuppressor protein p53 by DNA-damaging agents. Oncogenc 8: 307-318, 1993.
30. Kimura E, Enns RE, Thiebaut F, et al: Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line. Cancer Chemother Pharmacol 32: 279-285, 1993.
31. Shen D-W, Akiyama S-I, Schoenlein P, et al: Characterisation of highlevel cisplatinresistant cell lines established from a human hepatoma cell line and human KB adenocarcinormt cells: cross-resistance and protein changes. Br J Cancer 71: 676-683, 1995.
32. Hao XY, Bergh J, Brodin O, et al: Acquired resistance to cisplatin and doxorubicin in a small cell lung carcinoma cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogcncsis 15: 1167-1173, 1994.
33. Ferguson AW, Flatow U, MacDonald NJ, et al: Increased sensitivity to cisplatin by nm23-transfected tumor cell lines. Cancer Res 56: 2931-2935, 1996.
34. Everse J and Kaplan NO: Lactate dehydrogenases: structure and function. Adv Enzymol Relat Areas Mol Biol 37: 61-133, 1973.
35. Cahn RD, Kaplan NO, Levine L, et al: Nature and development of lactic dehydrogenases. Science 136: 962-969, 1962.
36. Pan L, Xu J, Isaacson PG: Cellular H- and M-type lactate dehydrogenase (LDH) isoenzymes and tumour diagnosis - An immunohistochemical assessment. J Pathol 163: 53-60, 1991.
37. Carda-Abella P, Perez-Cuadrado S, Lara-Baruque S, et al LDH isoenzymc patterns in tumors, polyps, and uninvolved mucosa of human cancerous colon. Cancer 40: 80-83, 1982.
38. Bosl GJ, Geller NL, Cirrincione C, et al: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43: 3403-3407, 1983.
39. Schwarts MK: Lactic dehydrogenase. An old enzyme reborn as a cancer marker? Am J Clin Pathol 96: 441-443, 1991.
40. Von Eyben FE, Blaabjerg O, Madsen EL, et al: Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours. Eur J Cancer 28: 410-415, 1992.
41. Von Eyben FE, De Graaff WE, Marrink J, et al: Serum lactate dehydrogenase isoenzyme 1 activity in patients with testicular germ cell tumor relates to the total number of copies of the short arms of chromosome 12 in the tumor. Mol Gen Genet 235: 140-146, 1992.
42. Nehar D, Mauduit C, Revol A, et al: Effect of epidermal growth factor / transforming growth factor α on lactate production in porcine Sertoli cells: glucose transport and lactate dehydrogenase isozymes as potential sites of action. Mol Cell Endocrinol 92: 45-53, 1993.
43. Kikuchi Y, Miyauchi M, Kizawa I, et al: Establishment of a cisplatin-resistant human ovarian cancer cell line. J Natl Cancer Inst 77: 1181-1185, 1986.
44. Grosse F, Nasheurer H, Scholtissek S, et al: Lactate dehydrogenase and glyceraldehyde-phosphate dehydrogenase are single-stranded DNA-binding proteins that affect the DNA-polymerase-α-primase complex. Eur J Biochcm 160: 459-467, 1986.
45. Williams KR, Roddigari S, Patel GL: Identification of a nucleic acid helix destabilizing protein from rat liver as lactate dehydrogenase-5. Proc Natl Acad Sci USA 82: 5260-5264, 1985.
46. Ronai Z: Glyeolytic enzymes as DNA binding proteins. Int J Biochem 25: 1073-1076, 1993.
47. Zhong X-H and Howard BD: Phosphotyrosine-containing lactate dehydrogenase is restricted to the nuclei of PC12 pheochromocytoma cells. Mol Cell Biol 10: 770-776, 1990.